Export 5 results:
Author Title Type [ Year(Desc)]
Filters: Author is Clark, Lorna  [Clear All Filters]
2010
S. Vasan, Schlesinger, S. J., Chen, Z., Hurley, A., Lombardo, A., Than, S., Adesanya, P., Bunce, C., Boaz, M., Boyle, R., Sayeed, E., Clark, L., Dugin, D., Boente-Carrera, M., Schmidt, C., Fang, Q., Huang, Y., Zaharatos, G. J., Gardiner, D. F., Caskey, M., Seamons, L., Ho, M., Dally, L., Smith, C., Cox, J., Gill, D., Gilmour, J., Keefer, M. C., Fast, P., and Ho, D. D., “Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.”, PLoS One, vol. 5, no. 1, p. e8816, 2010.
S. Vasan, Schlesinger, S. J., Huang, Y., Hurley, A., Lombardo, A., Chen, Z., Than, S., Adesanya, P., Bunce, C., Boaz, M., Boyle, R., Sayeed, E., Clark, L., Dugin, D., Schmidt, C., Song, Y., Seamons, L., Dally, L., Ho, M., Smith, C., Markowitz, M., Cox, J., Gill, D. K., Gilmour, J., Keefer, M. C., Fast, P., and Ho, D. D., “Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.”, PLoS One, vol. 5, no. 1, p. e8617, 2010.
2011
S. Vasan, Hurley, A., Schlesinger, S. J., Hannaman, D., Gardiner, D. F., Dugin, D. P., Boente-Carrera, M., Vittorino, R., Caskey, M., Andersen, J., Huang, Y., Cox, J. H., Tarragona-Fiol, T., Gill, D. K., Cheeseman, H., Clark, L., Dally, L., Smith, C., Schmidt, C., Park, H. H., Kopycinski, J. T., Gilmour, J., Fast, P., Bernard, R., and Ho, D. D., “In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.”, PLoS One, vol. 6, no. 5, p. e19252, 2011.
2012
M. C. Keefer, Gilmour, J., Hayes, P., Gill, D., Kopycinski, J., Cheeseman, H., Cashin-Cox, M., Naarding, M., Clark, L., Fernandez, N., Bunce, C. A., Hay, C. M., Welsh, S., Komaroff, W., Hachaambwa, L., Tarragona-Fiol, T., Sayeed, E., Zachariah, D., Ackland, J., Loughran, K., Barin, B., Cormier, E., Cox, J. H., Fast, P., and Excler, J. - L., “A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.”, PLoS One, vol. 7, no. 8, p. e41936, 2012.
2015
G. Omosa-Manyonyi, Mpendo, J., Ruzagira, E., Kilembe, W., Chomba, E., Roman, F., Bourguignon, P., Koutsoukos, M., Collard, A., Voss, G., Laufer, D., Stevens, G., Hayes, P., Clark, L., Cormier, E., Dally, L., Barin, B., Ackland, J., Syvertsen, K., Zachariah, D., Anas, K., Sayeed, E., Lombardo, A., Gilmour, J., Cox, J., Fast, P., and Priddy, F., “A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.”, PLoS One, vol. 10, no. 5, p. e0125954, 2015.